IDEAYA Biosciences (IDYA) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IDEAYA Biosciences (IDYA) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 34.4% versus a gain of 7.5%. Telix Pharmaceuticals is the larger company by market cap ($3.74 billion vs $3.48 billion), about 1.1 times the size, while IDEAYA Biosciences is growing revenue faster (+3024.4% vs +55.6%). Telix Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.9% versus -52.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | TLX |
|---|---|---|
| Share price | $36.06 | $11.01 |
| Market cap | $3.48B | $3.74B |
| 1-day change | -0.55% | -0.99% |
| YTD return | +4.31% | +47.00% |
| 1-year return | +34.35% | +7.52% |
| 5-year return | +55.90% | — |
| P/E ratio (TTM) | — | 110.10 |
| EPS (TTM) | $-1.94 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $218.71M | $803.79M |
| Revenue growth (YoY) | +3024.43% | +55.61% |
| Net income (latest FY) | $-113.70M | $-7.13M |
| Gross margin | — | 53.05% |
| Operating margin | -72.84% | 3.70% |
| Net margin | -51.99% | -0.89% |
| 52-week high | $42.68 | $13.11 |
| 52-week low | $26.05 | $6.28 |
| Distance from 52-week high | -15.51% | -16.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +46.28% | +85.47% |
| Average volume | 779.15K | 261.67K |
| Shares outstanding | 96.49M | 339.78M |
| Employees | 145 | 1,120 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDYA has outperformed TLX by 26.8 percentage points over the past year.
- Telix Pharmaceuticals is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +55.61%).
- The two companies sit in different sectors: IDEAYA Biosciences in Healthcare and Telix Pharmaceuticals in Health Care.
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Healthcare · Biotechnology · 145 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
IDYA vs TLX FAQ
Which is bigger, IDEAYA Biosciences or Telix Pharmaceuticals?
Telix Pharmaceuticals (TLX) is larger, with a market capitalization of $3.74B compared with $3.48B for IDEAYA Biosciences (IDYA).
Which stock has performed better over the past year, IDYA or TLX?
IDYA returned +34.35% over the past 12 months, compared with +7.52% for TLX (price return, excluding dividends). Past performance does not predict future results.
Are IDEAYA Biosciences and Telix Pharmaceuticals in the same industry?
No. IDEAYA Biosciences is in the Healthcare sector, while Telix Pharmaceuticals is in Health Care.